Vascular endothelial growth factor (VEGF) has been shown to play a central role in the pathophysiologic process underlying neovascular eye diseases. As such, anti-VEGF-based pharmacologic agents have emerged as a highly effective treatment modality for various visually debilitating retinal and choroidal vascular pathologies. The introduction of these pharmacologic agents directly into the vitreous cavity by means of an injection through the pars plana has become a widely performed ophthalmic procedure both locally and overseas.
Intravitreal Injections